DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)

Information source: Northumbria Healthcare NHS Foundation Trust
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rheumatoid Arthritis

Intervention: Etoricoxib (Drug); Diclofenac (Drug)

Phase: Phase 4

Status: Not yet recruiting

Sponsored by: Northumbria Healthcare NHS Foundation Trust

Overall contact:
David J Walker, MD, Phone: 01912231685, Email: david.walker@nuth.nhs.uk

Summary

The purpose of this study is to explore the effect of Etoricoxib compared to Diclofenac on physical activity in RA subjects with early morning pain and stiffness.

Clinical Details

Official title: Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis.

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To explore the effect of Etoricoxib compared to Diclofenac on physical activity in RA subjects with Early morning pain and stiffness.

Secondary outcome: To explore the effect of Etoricoxib compared to Diclofenac on average daily pain scores, fatigue scores, and quality of life.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male and female subjects aged 18 years and over.

- Subjects who are NSAID tolerant.

- Subjects with a clinical diagnosis of rheumatoid arthritis.

- Subjects who are willing to complete QOL questionnaires.

- Written informed consent

Exclusion Criteria:

- Co-occurrence of other disabling conditions in addition to rheumatoid arthritis

likely to warrant the persistent use of escape analgesia.

- Subjects who have received an intra-articular or muscular steroid injection within 3

months of study entry or in whom such treatment is planned within the study period.

- Subjects scheduled for elective surgery of the disease site or any other elective

major surgery which would fall within the study period.

- Severe respiratory impairment.

- Clinically significant hepatic or renal dysfunction, subjects whose LFTs and serum

creatinine is outside normal recognized limits.

- Subjects with convulsive disorders, head injury, shock, reduced level of

consciousness of uncertain origin, intracranial lesions or increased intracranial pressure.

- Subjects with a known allergy or hypersensitivity to NSAIDs.

- Subjects with unstable gastro-intestinal complications or disease.

- Subjects who currently abuse alcohol or drugs, or have a recent history of alcohol or

drug abuse, or who in the Investigator's opinion, have previously demonstrated drug-seeking behaviour.

- Subjects who are currently participating in another clinical research study involving

a new chemical entity or who have participated in a clinical study within the previous 30 days.

Locations and Contacts

David J Walker, MD, Phone: 01912231685, Email: david.walker@nuth.nhs.uk

Northumbria Healthcare NHS Foundation Trust, North Shields, Tyne and Wear NE29 8NH, United Kingdom; Not yet recruiting
David J Walker, MD, Principal Investigator
Additional Information

Starting date: April 2010
Last updated: February 10, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017